Brooke Harrow
Overview
Explore the profile of Brooke Harrow including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
78
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gelderblom H, Bhadri V, Stacchiotti S, Bauer S, Wagner A, van de Sande M, et al.
Lancet
. 2024 Jun;
403(10445):2709-2719.
PMID: 38843860
Background: Tenosynovial giant cell tumour (TGCT) is a locally aggressive neoplasm for which few systemic treatment options exist. This study evaluated the efficacy and safety of vimseltinib, an oral, switch-control,...
2.
Brown J, Harrow B, Marciniak A, McCarthy C, Houchard A, Cirneanu L, et al.
Drugs Real World Outcomes
. 2024 Jan;
11(2):195-207.
PMID: 38265633
Background And Objective: The tyrosine kinase inhibitors cabozantinib and axitinib have been widely used in England to treat advanced renal cell carcinoma following prior vascular endothelial growth factor-targeted therapy, but...
3.
Gelderblom H, Jones R, Blay J, George S, von Mehren M, Zalcberg J, et al.
Eur J Cancer
. 2023 Aug;
192:113245.
PMID: 37598656
Purpose: In the INTRIGUE trial, ripretinib showed no significant difference versus sunitinib in progression-free survival for patients with advanced gastrointestinal stromal tumour (GIST) previously treated with imatinib. We compared the...
4.
Harrow B, Fagnani F, Nevoret C, Truong-Thanh X, de Zelicourt M, de Mestier L
Adv Ther
. 2022 Oct;
40(1):387-388.
PMID: 36315341
No abstract available.
5.
Harrow B, Fagnani F, Nevoret C, Truong-Thanh X, de Zelicourt M, de Mestier L
Adv Ther
. 2022 Mar;
39(6):3059-3060.
PMID: 35347661
No abstract available.
6.
Harrow B, Fagnani F, Nevoret C, Truong-Thanh X, de Zelicourt M, de Mestier L
Adv Ther
. 2022 Feb;
39(4):1754-1771.
PMID: 35190997
Introduction: Long-acting somatostatin analogues such as lanreotide autogel (LAN) and octreotide long-acting release (OCT) are recommended as first-line treatment for patients with neuroendocrine tumors (NETs). However, only few real-world studies...
7.
Gallagher J, Heap K, Carroll S, Travers K, Harrow B, Westin S
Future Oncol
. 2019 Nov;
15(36):4197-4206.
PMID: 31707856
To assess real-world occurrence of common clinical trial-reported adverse events (AE) among patients with recurrent ovarian cancer initiating niraparib 200 mg/day. This retrospective observational study used physician-extracted anonymized medical record...
8.
Neeser K, ONeil W, Stern L, Harrow B, Travers K
J Comp Eff Res
. 2019 Apr;
8(8):577-587.
PMID: 30935213
To estimate financial implications of adopting niraparib as maintenance treatment in recurrent ovarian cancer. A model was developed to estimate the budget impact of treating patients with niraparib compared with...
9.
Harrow B, Sedaghat A, Caldwell-Tarr A, Dufour R
J Manag Care Spec Pharm
. 2016 Nov;
22(12):1426-1436.
PMID: 27882840
Background: Allergic rhinitis (AR) is a common condition that can be treated with a number of different therapies. Treatments such as intranasal antihistamines (INAs) and intranasal steroids (INSs) are widely...
10.
Price D, Harrow B, Small M, Pike J, Higgins V
World Allergy Organ J
. 2015 Sep;
8(1):26.
PMID: 26417397
Background: Inhaled asthma medications are the mainstay of treatment for chronic asthma. However, nonadherence rates for long-term inhaler therapy among adults are estimated to exceed 50 %. Nonadherence is associated...